Simple Blood Test Could Replace Painful Bone Biopsy

The new chip-based blood test vastly improves testing performance and accuracy over previous chips for multiple myeloma, said researchers. The findings of the study have been published in the journal Integrative Biology.

The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy.

Multiple Myeloma / Plasma Cell Myeloma–Symptoms-Treatment-Prognosis-Support Group
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Mehta’s ‘Water’ , declared that she had the incurable Multiple Myeloma.

‘Low-cost chip-based blood test can deliver the same diagnostic information as a bone biopsy - but using a simple blood draw instead.’

Tweet it Now

During that procedure, doctors insert a bone-biopsy needle through an incision to get a bone marrow sample -- or make a larger incision and remove a section of bone via surgery.

Bone biopsies are used to guide treatment of certain other cancers, such as many types of leukemia.

This test will be able to help clinicians determine the stage of the disease, what type of drug will best treat the disease and monitor for signs of recurrence if the disease goes into remission, the researchers said.

Biopsy - Introduction
Encyclopedia section of medindia explains in brief Introduction To Biopsy

"For the last 10 years, we've been developing a blood-based test for a variety of cancer diseases -- one of them is multiple myeloma," said Steven Soper, Professor at University of Kansas in the US.

"We'll be able to eliminate the need for bone-marrow biopsies and allow the clinician to determine the best way to treat the disease using a blood draw," Soper added.

Skeletal Defect Leads to Increased Fracture Risk Among Diabetics
Individuals with type 2 diabetes have structural defects in their bones which could increase their risk for fractures.

Soper said that previous plastic chips to test for multiple myeloma had shortcomings, such as picking up regular blood cells instead of multiple myeloma cells in the blood.

High levels of circulating multiple myeloma cells are linked with more aggressive disease and worse outcomes, so a sensitive test is vital for assessing the state of the disease in a patient and devising the most effective therapy.

Post-Bone Marrow Transplant, Biomarker Detects Graft-Versus-Host-Disease in Cancer Patients
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia,

"What's really nice is we can produce these chips for a couple of dollars per chip, which makes it really appropriate for testing in a clinical setting," Soper said.

The new test for multiple myeloma developed by the team will be brought to market by BioFluidica, a San Diego-based company.

"Patients will soon be benefiting from this technology," Soper said.

Source-IANS